Fundraising September 15, 2024 – October 1, 2024 About fundraising

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line...

Annals of Oncology 2020 / 09 Vol. 31

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

Choueiri, T.K., Powles, T., Burotto, M., Bourlon, M.T., Zurawski, B., Oyervides Juárez, V.M., Hsieh, J.J., Basso, U., Shah, A.Y., Suarez, C., Hamzaj, A., Barrios, C.H., Richardet, M., Pook, D., Tomit
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.2257
Date:
September, 2020
File:
PDF, 79 KB
2020
Conversion to is in progress
Conversion to is failed